Drug Interactions Database

6278 interactions from BNF 85 - Check your medicines

Source: BNF 85
lumacaftor ketoconazole

decreases exposure

Unknown Theoretical
lumacaftor levonorgestrel

decreases efficacy

Unknown Theoretical
lumacaftor macrolides

decreases exposure

Unknown Theoretical
lumacaftor norethisterone

decreases efficacy

Unknown Theoretical
lumacaftor pibrentasvir

decreases exposure

Unknown Theoretical
lumacaftor posaconazole

decreases exposure

Unknown Theoretical
lumacaftor sirolimus

decreases exposure

Unknown Theoretical
lumacaftor subdermaletonogestrel

decreases efficacy

Unknown Theoretical
lumacaftor ulipristal

decreases efficacy

Unknown Theoretical
lumacaftor voriconazole

decreases exposure

Unknown Theoretical
macrolides afatinib

increases exposure

Unknown Study
macrolides antimalarials

increases risk of seriouscardiovascularadverseeffects

Unknown Theoretical
macrolides berotralstat

increases exposure

Unknown Study
macrolides betablockers,non-selective

increases exposure

Unknown Study
macrolides chloroquine

increases risk of seriouscardiovascularadverseeffects

Unknown Theoretical
macrolides hydroxychloroquine

increases risk of seriouscardiovascularadverseeffects

Unknown Theoretical
macrolides insulin

increases risk of severehypoglycaemia

Unknown Theoretical
macrolides nadolol

increases exposure

Unknown Study
macrolides nintedanib

increases exposure

Unknown Study
macrolides pibrentasvir

increases exposure

Unknown Theoretical
macrolides relugolix

increases exposure

Unknown Study
macrolides sulfonylureas

increases exposure

Unknown Theoretical
macrolides tigecycline

increases exposure

Unknown Anecdotal
macrolides topotecan

increases exposure

Unknown Study
macrolides trametinib

increases concentration

Unknown Theoretical
macrolides vincaalkaloids

increases exposure

Unknown Theoretical
macrolidesgivenwithapotentcyp2c19 inhibitor tofacitinib

increases exposure

Unknown Study
magnesium roxadustat

decreases exposure

Unknown Theoretical
mao-binhibitors amfetamines

increases risk of severehypertension

Unknown Theoretical
mao-binhibitors linezolid

increases risk of adverseeffects

Unknown Theoretical
maois,irreversible atomoxetine

increases risk of adverseeffects

Unknown Theoretical
maois,irreversible beta

increases risk of cardiovascularadverseeffects

Unknown Anecdotal
maois,irreversible doxapram

increases effects

Unknown Theoretical
maois,irreversible linezolid

increases risk of adverseeffects

Unknown Theoretical
maois,irreversible phenothiazines

increases risk of neurolepticmalignantsyndrome

Unknown Theoretical
maois,irreversible rizatriptan

increases exposure

Unknown Theoretical
maois,irreversible sumatriptan

increases exposure

Unknown Theoretical
maois,irreversible triptans

increases exposure

Unknown Theoretical
maois,irreversible zolmitriptan

increases exposure

Unknown Theoretical
mefloquine betablockers,non-selective

increases risk of bradycardia

Unknown Theoretical
mefloquine betablockers,selective

increases risk of bradycardia

Unknown Theoretical
mefloquine calciumchannelblockers

increases risk of bradycardia

Unknown Theoretical
mefloquine digoxin

increases risk of bradycardia

Unknown Theoretical
memantine apomorphine

increases effects

Unknown Theoretical
memantine bromocriptine

increases effects

Unknown Theoretical
memantine cabergoline

increases effects

Unknown Theoretical
memantine dopaminereceptoragonists

increases effects

Unknown Theoretical
memantine levodopa

increases effects

Unknown Theoretical
memantine pramipexole

increases effects

Unknown Theoretical
memantine quinagolide

increases effects

Unknown Theoretical
Important: This database uses data from the British National Formulary (BNF 85). It is for informational purposes only and is not a substitute for professional medical advice.